Elan has won US regulatory approval for Prialt, its treatment for severe chronic pain.
The company said the drug won approval from the US Food and Drug Administration for use in an infusion system made by device maker Medtronic Inc.
Elan shares rose by 80 cent, or 4%, to €19.80 today on the Dublin stock exchange.
FDA approval of Prialt was based on the treatment of more than 1,200 patients and three Phase III clinical trials, which evaluated the efficacy and safety of IT Prialt in patients with severe chronic pain that was not adequately managed despite a regimen of systemic and/or IT analgesic and other drugs.
Prialt is part of a group of non-opioid analgesics known as N-type calcium channel blockers. It's the synthetic equivalent of a naturally occurring conopeptide found in a marine snail known as Conus magus.
